Search research articles
Contact Us
Filters
Showing results (611-620 of 669) with videos related to
Page
of 67
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN
|
May 2, 2009
NCCN clinical practice guidelines in oncology: palliative care
Michael H Levy, Anthony Back, Costantino Benedetti, et al.
Scientific Reports
|
March 9, 2018
Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma
Nicholas A Gherardin, Liyen Loh, Lorenztino Admojo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 25, 2022
External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer
Bhavna Oza, Tim Eisen, Eleni Frangou, et al.
Immunology and Cell Biology
|
February 14, 2018
Human blood MAIT cell subsets defined using MR1 tetramers
Nicholas A Gherardin, Michael Nt Souter, Hui-Fern Koay, et al.
HIV Medicine
|
November 2, 2025
Inflammatory profiles in older people with and without HIV in rural Uganda
Alejandra Cova, Christine S Ritchie, Masette Godfrey, et al.
The New England Journal of Medicine
|
June 13, 2025
Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin
David J Curtis, Sushrut S Patil, John Reynolds, et al.
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine
|
April 3, 2022
Mapping the future for research in emergency medicine palliative care: A research roadmap
Emily L Aaronson, Rebecca J Wright, Christine S Ritchie, et al.
Haematologica
|
June 30, 2022
The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cells
Kelden Richardson, Simon P Keam, Joe Jiang Zhu, et al.
The Lancet. Oncology
|
March 29, 2012
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial
Nicholas D James, Matthew R Sydes, Malcolm D Mason, et al.
European Urology
|
July 3, 2014
Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial
Gerhardt Attard, Matthew R Sydes, Malcolm D Mason, et al.
Page
of 67
Search research articles
Search
Showing results (611-620 of 669) with videos related to
Sort By:
Page
of 67
Journal of the National Comprehensive Cancer Network : JNCCN
|
May 2, 2009
NCCN clinical practice guidelines in oncology: palliative care
Michael H Levy, Anthony Back, Costantino Benedetti, et al.
Scientific Reports
|
March 9, 2018
Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma
Nicholas A Gherardin, Liyen Loh, Lorenztino Admojo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 25, 2022
External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer
Bhavna Oza, Tim Eisen, Eleni Frangou, et al.
Immunology and Cell Biology
|
February 14, 2018
Human blood MAIT cell subsets defined using MR1 tetramers
Nicholas A Gherardin, Michael Nt Souter, Hui-Fern Koay, et al.
HIV Medicine
|
November 2, 2025
Inflammatory profiles in older people with and without HIV in rural Uganda
Alejandra Cova, Christine S Ritchie, Masette Godfrey, et al.
The New England Journal of Medicine
|
June 13, 2025
Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin
David J Curtis, Sushrut S Patil, John Reynolds, et al.
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine
|
April 3, 2022
Mapping the future for research in emergency medicine palliative care: A research roadmap
Emily L Aaronson, Rebecca J Wright, Christine S Ritchie, et al.
Haematologica
|
June 30, 2022
The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cells
Kelden Richardson, Simon P Keam, Joe Jiang Zhu, et al.
The Lancet. Oncology
|
March 29, 2012
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial
Nicholas D James, Matthew R Sydes, Malcolm D Mason, et al.
European Urology
|
July 3, 2014
Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial
Gerhardt Attard, Matthew R Sydes, Malcolm D Mason, et al.
Page
of 67